BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21997879)

  • 1. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
    Reardon DA; Herndon JE; Peters K; Desjardins A; Coan A; Lou E; Sumrall A; Turner S; Sathornsumetee S; Rich JN; Boulton S; Lipp ES; Friedman HS; Vredenburgh JJ
    J Neurooncol; 2012 Mar; 107(1):213-21. PubMed ID: 21997879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
    Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
    Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
    Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
    J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
    Sahebjam S; Garoufalis E; Guiot MC; Muanza T; Del Maestro R; Petrecca K; Sharma R; Kavan P
    Can J Neurol Sci; 2013 Mar; 40(2):241-6. PubMed ID: 23419575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
    Chen C; Huang R; MacLean A; Muzikansky A; Mukundan S; Wen PY; Norden AD
    J Neurooncol; 2013 Nov; 115(2):267-76. PubMed ID: 23974656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma.
    Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
    Neurosurgery; 2010 Jul; 67(1):87-93. PubMed ID: 20559095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
    Quant EC; Norden AD; Drappatz J; Muzikansky A; Doherty L; Lafrankie D; Ciampa A; Kesari S; Wen PY
    Neuro Oncol; 2009 Oct; 11(5):550-5. PubMed ID: 19332770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma.
    Wiestler B; Radbruch A; Osswald M; Combs SE; Jungk C; Winkler F; Bendszus M; Unterberg A; Platten M; Wick W; Wick A
    J Neurooncol; 2014 Mar; 117(1):85-92. PubMed ID: 24458956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts.
    Lorgis V; Maura G; Coppa G; Hassani K; Taillandier L; Chauffert B; Apetoh L; Ladoire S; Ghiringhelli F
    J Neurooncol; 2012 Apr; 107(2):351-8. PubMed ID: 22076449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
    Kurz SC; Cabrera LP; Hastie D; Huang R; Unadkat P; Rinne M; Nayak L; Lee EQ; Reardon DA; Wen PY
    Neurology; 2018 Oct; 91(14):e1355-e1359. PubMed ID: 30171077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.
    Scott BJ; Quant EC; McNamara MB; Ryg PA; Batchelor TT; Wen PY
    Neuro Oncol; 2010 Jun; 12(6):603-7. PubMed ID: 20156808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.
    Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
    Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD
    J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
    Demirci U; Tufan G; Aktas B; Balakan O; Alacacioglu A; Dane F; Engin H; Kaplan MA; Gunaydin Y; Ozdemir NY; Tugba Unek I; Karaca H; Akman T; Sonmez OU; Coskun U; Harputluoglu H; Sevinc A; Tonyali O; Buyukberber S; Benekli M
    J Cancer Res Clin Oncol; 2013 May; 139(5):829-35. PubMed ID: 23400732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
    J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
    Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L
    J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
    Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.